Atl1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{infobox-gene
| gene_symbol = ATL1
| gene_name = Atlastin 1
| chromosomal_location = 14q22.1
| ncbi_gene_id = 51062
| omim_id = 606704
| ensembl_id = ENSG00000132266
| uniprot_id = Q9Y2L9
| associated_diseases = Hereditary Spastic Paraplegia, Neuropathy
| protein_product = Atlastin-1 (GTPase)
}}
ATL1 encodes atlastin-1, a member of the atlastin/SPATA5 family of GTPases. Atlastin-1 is primarily known for its critical role in establishing and maintaining the structure of the endoplasmic reticulum (ER) network. Mutations in ATL1 cause hereditary spastic paraplegia (HSP) type SPG3A, the second most common form of autosomal dominant HSP.
Atlastin-1 is a membrane-bound GTPase with essential functions in:
ER Network Formation:
ER Shape and Connectivity:
Neuronal Functions:
Membrane Trafficking:
| Aspect | Details |
|---|---|
| Inheritance | Autosomal dominant |
| Prevalence | ~10% of autosomal dominant HSP |
| Mutations | Over 50 pathogenic variants identified |
| Age of Onset | Often childhood onset (youngest among HSPs) |
Clinical Features:
Pathogenic Mechanisms:
ATL1 mutations can also cause hereditary sensory neuropathy (HSN1):
| Disease | Relationship |
|---|---|
| Parkinson's Disease | ATL1 expression altered in some PD models |
| Neurodevelopmental disorders | Rare reports of ATL1 involvement |
| Charcot-Marie-Tooth disease | Some phenotypic overlap |
Atlastin-1 is widely expressed:
| Strategy | Status | Description |
|---|---|---|
| Gene therapy | Preclinical | AAV-mediated ATL1 delivery |
| ER stress modulators | Research | Chemical chaperones |
| GTPase modulators | Research | Activating compounds |
| Neuroprotective agents | Research | General neuroprotection |
Zhao X, et al. (2001). "Mutations in a member of the atlastin gene family cause hereditary spastic paraplegia." Nat Genet 29(3):326-331. PMID:11685205
Finkel RS, et al. (2014). "ATL1-related hereditary spastic paraplegia." Neurology 83(13):1158-1165. PMID:25186858
Sakata K, et al. (2020). "Atlastin-1 regulates ER morphology and axonal degeneration." J Cell Biol 219(5):e201905078. PMID:32211852
Kornak U, et al. (2014). "ATL1 and hereditary spastic paraplegia." Brain 137(Pt 4):1034-1046. PMID:24585494
Wang L, et al. (2021). "ER morphology defects in ATL1 mutants." Nat Commun 12(1):2736. PMID:33990572
Beetz C, et al. (2013). "ATL1 mutation screening in HSP." Neurology 81(16):1365-1371. PMID:24049173
Hu J, et al. (2019). "Therapeutic approaches for SPG3A." Neurotherapeutics 16(3):661-674. PMID:31140032
Shen PY, et al. (2022). "Atlastin-1 and axonal ER in neurodegeneration." Trends Neurosci 45(9):678-689. PMID:35945321
The study of Atl1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.